Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies.
Muraro E, Martorelli D, Turchet E, Miolo G, Scalone S, Comaro E, Talamini R, Mastorci K, Lombardi D, Perin T, Carbone A, Veronesi A, Crivellari D, Dolcetti R. Muraro E, et al. Among authors: comaro e. Breast Cancer Res. 2011;13(6):R117. doi: 10.1186/bcr3060. Breast Cancer Res. 2011. PMID: 22112244 Free PMC article.
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.
Muraro E, Comaro E, Talamini R, Turchet E, Miolo G, Scalone S, Militello L, Lombardi D, Spazzapan S, Perin T, Massarut S, Crivellari D, Dolcetti R, Martorelli D. Muraro E, et al. Among authors: comaro e. J Transl Med. 2015 Jun 27;13:204. doi: 10.1186/s12967-015-0567-0. J Transl Med. 2015. PMID: 26116238 Free PMC article. Clinical Trial.
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.
Miolo G, Muraro E, Martorelli D, Lombardi D, Scalone S, Spazzapan S, Massarut S, Perin T, Viel E, Comaro E, Talamini R, Bidoli E, Turchet E, Crivellari D, Dolcetti R. Miolo G, et al. Among authors: comaro e. BMC Cancer. 2014 Dec 15;14:954. doi: 10.1186/1471-2407-14-954. BMC Cancer. 2014. PMID: 25512030 Free PMC article. Clinical Trial.
Predictive Value of CD8 Expression and FoxP3 Methylation in Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy in a Non-endemic Area.
Muraro E, Vaccher E, Furlan C, Fratta E, Fanetti G, Fae' DA, Martorelli D, Cangemi M, Polesel J, Navarria F, Gobitti C, Comaro E, Scaini C, Pratesi C, Zanussi S, Lupato V, Grando G, Giacomarra V, Sulfaro S, Barzan L, Dolcetti R, Steffan A, Canzonieri V, Franchin G. Muraro E, et al. Among authors: comaro e. Pathol Oncol Res. 2020 Oct;26(4):2459-2467. doi: 10.1007/s12253-020-00859-3. Epub 2020 Jun 21. Pathol Oncol Res. 2020. PMID: 32564263 Free article.
Local High-Dose Radiotherapy Induces Systemic Immunomodulating Effects of Potential Therapeutic Relevance in Oligometastatic Breast Cancer.
Muraro E, Furlan C, Avanzo M, Martorelli D, Comaro E, Rizzo A, Fae' DA, Berretta M, Militello L, Del Conte A, Spazzapan S, Dolcetti R, Trovo' M. Muraro E, et al. Among authors: comaro e. Front Immunol. 2017 Nov 6;8:1476. doi: 10.3389/fimmu.2017.01476. eCollection 2017. Front Immunol. 2017. PMID: 29163540 Free PMC article.
Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.
Montico B, Lapenta C, Ravo M, Martorelli D, Muraro E, Zeng B, Comaro E, Spada M, Donati S, Santini SM, Tarallo R, Giurato G, Rizzo F, Weisz A, Belardelli F, Dolcetti R, Dal Col J. Montico B, et al. Among authors: comaro e. Oncoimmunology. 2017 Jul 31;6(11):e1356964. doi: 10.1080/2162402X.2017.1356964. eCollection 2017. Oncoimmunology. 2017. PMID: 29147614 Free PMC article.
Emerging Role of Immunomonitoring to Predict the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Radical Radiation Therapy.
Cangemi M, Montico M, Trovo M, Minatel E, Di Gregorio E, Corona G, Giordari F, Comaro E, Colizzi F, Baboçi L, Steffan A, Revelant A, Muraro E. Cangemi M, et al. Among authors: comaro e. Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):608-621. doi: 10.1016/j.ijrobp.2022.09.079. Epub 2022 Oct 3. Int J Radiat Oncol Biol Phys. 2023. PMID: 36202181
Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors.
Muraro E, Montico B, Lum B, Colizzi F, Giurato G, Salvati A, Guerrieri R, Rizzo A, Comaro E, Canzonieri V, Anichini A, Del Vecchio M, Mortarini R, Milione M, Weisz A, Pizzichetta MA, Simpson F, Dolcetti R, Fratta E, Sigalotti L. Muraro E, et al. Among authors: comaro e. Front Immunol. 2024 Mar 6;15:1336566. doi: 10.3389/fimmu.2024.1336566. eCollection 2024. Front Immunol. 2024. PMID: 38510242 Free PMC article.